Aims: Peripheral neuropathy (PN) is a common condition whose incidence is approximately 8% in elderly persons. Neuropathic pain (NeP) has a significant incidence in the general population and affects more than half of all patients with PN. The pathophysiology of PN is characterized by lesions of myelin-producing Schwann cells in peripheral nerves. Regeneration/protection of the myelin sheath after a nerve lesion is a fundamental element of repair in PN. Nucleotides such as uridine monophosphate (UMP) have proven to be efficacious in treating the cause of the myelin sheath lesion in several experimental and clinical models. Our objective was to evaluate clinical improvement in patients with PN and NeP treated with a combination of UMP+folic acid+vitamin B₁₂ (Keltican^®). Patients and Methods: We performed an exploratory, open-label, multicenter, study of 212 patients followed for 2 months. Pain was assessed using the painDETECT questionnaire (PDQ). Results: The intensity of the NeP assessed at the time of the consultation progressed favorably and decreased significantly (p<0.001) in all the types of PN included. The global score for pain assessed using PDQ decreased from 17.5 points to 8.8 points at the final evaluation (p<0.001). Nonsteroidal anti-inflammatory drugs were decreased/withdrawn in 77.4% of patients. Conclusions: The combination of UMP+folic acid+vitamin B₁₂ is effective against NeP associated with PN. It leads to statistically significant reductions not only in the total PDQ score but also in the intensity of pain, number of areas affected, and pain radiation. Furthermore, it makes it possible to reduce the dosage of concomitant medication.

Keywords:

References

1 Hughes RA. Peripheral neuropathy. BMJ 324(7335), 466–469 (2002).
MedlineGoogle Scholar
2 Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J. Neurol. Neurosurg. Psychiatr. 62(4), 310–318 (1997).
Medline CASGoogle Scholar
3 Peripheral Neuropathy (3rd Edition). Dick PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (Eds). WB Saunders, Philadelphia, PA, USA, 747–775 (1993).
Google Scholar
4 Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and neuropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43(4), 817–824 (1993).
Medline CASGoogle Scholar
5 Berger A, Dukes EM, Oster G. Clinical characteristics and economics costs of patients with painful neuropathic disorders. J. Pain 5(3), 143–149 (2004).
MedlineGoogle Scholar
6 Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin. J. Pain 18(6), 355–365 (2002).
MedlineGoogle Scholar
7 Dick PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann. Neurol. 10(3), 222–226 (1981).
MedlineGoogle Scholar
8 Toth C, Au S. A prospective identification of neuropathic pain in specific polyneuropathy syndromes and response to pharmacological therapy. Pain 138(3), 657–666 (2008).
MedlineGoogle Scholar
9 McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur. J. Pain 10(2), 127–135 (2006).
MedlineGoogle Scholar
10 Ide C. Peripheral nerve regeneration. Neurosci. Res. 25(2), 101–121 (1996).
Medline CASGoogle Scholar
11 Navarro X, Vivó M, Valero-Cabré A. Neural plasticity after peripheral nerve injury and regeneration. Prog. Neurobiol. 82(4), 163–201 (2007).
Medline CASGoogle Scholar
12 Wattig B, Schalow G, Heydenreich F, Warzok R, Cervós-Navarro J. Enhancement of nerve fibre regeneration by nucleotides after peripheral nerve crush damage. Electrophysiologic and morphometric investigations. Arzneimittelforschung 42, 1075–1078 (1992).
Medline CASGoogle Scholar
13 Wattig B, Schalow G, Madauss M, Heydenreich F, Warzok R, Cervós-Navarro J. Acceleration of nerve and muscle regeneration by administration of nucleotides – electroneurophysiological and morphometrical investigations. Acta Histochem. Suppl. 42, 333–339 (1992)..
Medline CASGoogle Scholar
14 Okada M, Nakagawa T, Minami M, Satoh M. Analgesic effects of intrathecal administration of P2Y nucleotide receptor agonists UTP and UDP in normal and neuropathic pain model in rats. J. Pharmacol. Exp. Ther. 303(1), 66–73 (2002)..
Medline CASGoogle Scholar
15 Andó RD, Méhész B, Gyires K, Illes P, Sperlágh B. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br. J. Pharmacol. 159(5), 1106–1117 (2010).
Medline CASGoogle Scholar
16 Martiañez T, Carrascal M, Lamarca A et al. UTP affects the Schwannoma cell line proteome through P2Y receptors leading to cytoskeletal reorganisation. Proteomics 12(1), 145–156 (2012).
Medline CASGoogle Scholar
17 Müller D. Treatment of neuropathic pain syndrome: results of an open study on the efficacy of a pyrimidine nucleotide preparation. Fortschr. Med. Orig. 120(4), 131–133 (2002).
MedlineGoogle Scholar
18 Gallai V, Mazzotta G, Montesi S, Sarchielli P, Del Gatto F. Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Acta Neurol. Scand. 86(1), 3–7 (1992).
Medline CASGoogle Scholar
19 Cartier L, Castillo JL, Verdugo R. Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study. Rev. Med. Chil. 124(5), 583–587 (1996).
Medline CASGoogle Scholar
20 Larm G, Ruckert U. [Neurotropic nutrients promote recovery after intervertebral disc operations]. Extracta Ortho. 2, 44–45 (2008).
Google Scholar
21 Peres-Serra J, Grau-Veciana JM, Barraquer-Bordás L. Therapeutic results of an association of CMP, UTP and vitamin B12 in 50 cases of peripheral neuropathy. N. Engl. J. Med. 6(64), (1972).
Google Scholar
22 Keltican®. Prescribing information in Portugal.
Google Scholar
23 Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Med. Res. Opin. 22(10), 1911–1920 (2006)..
MedlineGoogle Scholar
24 Perucca E, Berlowitz D, Birnbaum A et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 68S, S49–S63 (2006)..
Google Scholar
25 Blanco Tarrio E, Gálvez Mateos R, Zamorano Bayarri E, López Gómez V, Pérez Páramo M. Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting. Clin. Drug Investig. 33(9), 633–645 (2013).
Medline CASGoogle Scholar

Vol. 4, No. 3

Metrics

Downloaded 478 times

History

Published online 23 June 2014

Published in print May 2014

Information

Keywords

Acknowledgements

We are grateful to the following people: A Garcia and A Sanz (Ferrer, Portugal) for their participation in the writing of the manuscript; R Santos, L Magalhães and V Pinheiro (Ferrer, Portugal) for coordinating study monitoring; and P Baptista and N Gonçalves (KeyPoint, Portugal) for the evaluation and statistical report.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Editorial assistance was provided by Content Ed Net.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download